15 years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives

Peter Valent; Emir Hadzijusufovic; Irina Sadovnik; Thomas W. Grunt; Barbara Peter; Michael Willmann; Harald Herrmann; Daniel Ivanov; Gregor Eisenwort; Heidrun Karlic; Georg Greiner; Karoline V. Gleixner; Thomas Rülicke; Maik Dahlhoff; Philipp Staber; Wolfgang R. Sperr; Michael Pfeilstöcker; Thomas Lion; Felix Keil; Gregor Hoermann

doi:10.1007/s12254-024-00966-w

You are here:

PHAIDRA
Detail o:3713

Open in new window

Title (eng)

15 years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives

Author

Peter Valent

Emir Hadzijusufovic

Irina Sadovnik

Thomas W. Grunt

Barbara Peter

Michael Willmann

Harald Herrmann

Daniel Ivanov

Gregor Eisenwort

Heidrun Karlic

Georg Greiner

Karoline V. Gleixner

Thomas Rülicke

Maik Dahlhoff

Philipp Staber

Wolfgang R. Sperr

Michael Pfeilstöcker

Thomas Lion

Felix Keil

Gregor Hoermann

Abstract (eng)

Cancer stem cells, also known as leukemic stem cells (LSC) in the context of leukemias, are an emerging topic in translational oncology and hematology. The Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO) was established in 2008 with the aim to translate LSC concepts into clinical practice. Major specific aims of the LBI HO are to identify LSC in various blood cell disorders and to improve anti-leukemic therapies by establishing LSC-targeting and LSC-eradicating approaches with the ultimate aim to translate these concepts into clinical practice. In addition, the LBI HO identified a number of diagnostic and prognostic LSC markers in various blood cell malignancies. Members of the LBI HO have also developed precision medicine tools and personalized medicine approaches around LSC in applied hematology. As a result, diagnosis, prognostication and therapy have improved in the past 10 years. Major disease models are myeloid leukemias and mast cell neoplasms. Finally, the LBI HO consortium launched several projects in the field of open innovation in science where patient-derived initiatives and their input supported the scientific community. Key aims for the future of the LBI HO are to develop LSC-related concepts and strategies further, with the long-term vision to cure more patients with hematologic malignancies.

Keywords (eng)

Acute Myeloid-LeukemiaCancer Stem-CellsTherapeutic TargetInitiating CellsProgenitor CellsMelanoma-CellsKinase DomainIdentificationMidostaurinHeterogeneity

Type (eng)

journal article

Language

[eng]

Persistent identifier

https://phaidra.vetmeduni.ac.at/o:3713

DOI

10.1007/s12254-024-00966-w

Is in series

Title (eng)

MEMO - Magazine of European Medical Oncology

Volume